Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Rhea-AI Summary

Halozyme (NASDAQ: HALO) announced a global collaboration and exclusive license agreement with Takeda (signed December 2025) to provide access to Halozyme's ENHANZE® rHuPH20 drug delivery technology for use with vedolizumab (marketed as ENTYVIO).

Under the agreement, Takeda will make an upfront payment to Halozyme, potential future development and commercial milestone payments, and Halozyme may receive up to low-mid single digit royalties on sales of vedolizumab combined with ENHANZE®. Vedolizumab is approved for IV and SC administration in various markets for adults with moderately to severely active Crohn's disease or ulcerative colitis.

Positive

• Exclusive global license to ENHANZE for vedolizumab
• Agreement includes upfront payment plus milestone payments
• Potential royalties up to low-mid single digits on combined product sales

Negative

• No financial amounts disclosed for the upfront or milestone payments
• Regulatory approvals for SC vedolizumab vary by market

News Market Reaction

-3.97%

1 alert

-3.97% News Effect

On the day this news was published, HALO declined 3.97%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Projected IBD population: more than 10 million people Share price: $75.11 52-week high: $79.50 +2 more

5 metrics

Projected IBD population more than 10 million people Estimated global IBD cases within the next decade

Share price $75.11 Pre-news current price for HALO

52-week high $79.50 HALO 52-week high level

Q3 2025 revenue $354,264,000 Total revenue for quarter ended Sep 30, 2025

Q3 2025 net income $175,225,000 Net income for quarter ended Sep 30, 2025

Market Reality Check

Price: $78.42 Vol: Volume 2,684,017 is above...

normal vol

$78.42 Last Close

Volume Volume 2,684,017 is above the 20-day average of 2,224,329 (relative volume 1.21). normal

Technical Shares at $75.11 are trading above the 200-day MA of $63.79 and about 5.52% below the 52-week high of $79.50.

Peers on Argus

HALO showed a positive pre-news change of 2.71%, while momentum data flagged pee...

1 Down

HALO showed a positive pre-news change of 2.71%, while momentum data flagged peer RVMD moving down (-6.78%) and other close peers (MRNA, ROIV, VRNA, MDGL) had mixed, modest moves. This points to a more stock-specific setup around HALO rather than a broad biotechnology-sector swing.

Historical Context

5 past events · Latest: Dec 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 18	Regulatory approval	Positive	-1.0%	FDA approved RYBREVANT FASPRO co-formulated with ENHANZE for EGFR+ mNSCLC.
Dec 08	Board change	Positive	-1.6%	Jim Lang elected to board, bringing extensive healthcare and analytics experience.
Dec 04	Legal outcome	Positive	-2.4%	German court granted preliminary injunction blocking Merck’s Keytruda SC launch.
Nov 25	Conference participation	Neutral	-1.6%	Company announced participation and webcast at Evercore healthcare conference.
Nov 18	M&A transaction	Positive	-0.7%	Closed Elektrofi acquisition, adding Hypercon formulation platform and new milestones.

Pattern Detected

Recent history shows multiple positive regulatory, legal, and strategic updates followed by modest negative price reactions, indicating a pattern of the stock trading down on good news.

Recent Company History

Over the last several months, Halozyme reported stronger Q3 results on Nov 3, 2025, completed a sizeable Elektrofi acquisition on Nov 18, 2025, and secured a preliminary injunction in Germany against Keytruda SC on Dec 4, 2025. It also gained U.S. FDA approval for RYBREVANT FASPRO co-formulated with ENHANZE on Dec 18, 2025 and added Jim Lang to its board on Dec 8, 2025. Despite these generally positive milestones, 24-hour price reactions after each event were slightly negative, so today’s Takeda ENHANZE collaboration fits into a backdrop where strong news has not always produced immediate upside.

Market Pulse Summary

This announcement adds another global partner, Takeda, to Halozyme’s ENHANZE® ecosystem by pairing t...

Analysis

This announcement adds another global partner, Takeda, to Halozyme’s ENHANZE® ecosystem by pairing the rHuPH20 technology with vedolizumab (ENTYVIO) for inflammatory bowel disease. It builds on recent milestones such as stronger Q3 2025 results and new ENHANZE-based approvals. Key factors to monitor include the timing and magnitude of potential milestone and royalty payments, clinical and regulatory progress for the ENHANZE-enabled vedolizumab program, and how this collaboration complements prior strategic moves like the Elektrofi acquisition and recent financing activities.

Key Terms

ENHANZE, recombinant human hyaluronidase PH20, rHuPH20, ulcerative colitis, +4 more

8 terms

ENHANZE technical

"access to Halozyme's ENHANZE® drug delivery technology, the leading proprieta"

Enhanze is a proprietary drug-delivery technology that uses an enzyme-based formulation to temporarily loosen the tissue just under the skin, allowing larger doses or faster absorption of injected medicines. For investors, it matters because it can turn complex intravenous treatments into simpler under-the-skin injections, improving patient convenience and uptake and creating potential revenue through licensing, royalties or higher product competitiveness—like adding a faster, smaller doorway for getting medicine into the body.

recombinant human hyaluronidase PH20 medical

"the leading proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), fo"

Recombinant human hyaluronidase PH20 is a lab-made form of a human enzyme that temporarily breaks down hyaluronan, the gel-like material in connective tissue, so injected fluids or medicines can spread and be absorbed more quickly under the skin. Investors care because it can turn treatments that require slow or expensive intravenous delivery into convenient subcutaneous injections, broadening patient access, lowering administration costs, and creating licensing or co-formulation revenue opportunities—like an adapter that lets a bulky device plug into an ordinary outlet.

rHuPH20 medical

"recombinant human hyaluronidase PH20 enzyme (rHuPH20), for use with vedolizumab."

rHuPH20 is a lab-made human enzyme that temporarily loosens the gel-like barrier between cells under the skin, acting like a short-lived gate that lets injected medicines spread more easily. For investors, it matters because pairing this enzyme with injectable drugs can turn slow, hospital-based infusions into quicker, higher-volume shots given under the skin, potentially lowering costs, expanding patient access, and creating licensing or partnership value.

ulcerative colitis medical

"People living with ulcerative colitis and Crohn's disease, as well as their heal"

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

Crohn's disease medical

"People living with ulcerative colitis and Crohn's disease, as well as their heal"

A chronic inflammatory condition of the digestive tract in which the body's immune response causes repeated damage and irritation, leading to symptoms like abdominal pain, persistent diarrhea, weight loss and fatigue. It matters to investors because it creates ongoing demand for medications, medical devices and care services, shapes healthcare spending and insurance costs, and drives research and regulatory activity—think of it as a long-term market for treatments where an overactive security system attacks a vital pipeline.

inflammatory bowel disease medical

"Crohn's disease and ulcerative colitis are the two main forms of inflammatory bo"

Inflammatory bowel disease is a group of long‑lasting conditions that cause repeated inflammation of the digestive tract, leading to symptoms like belly pain, diarrhea, bleeding and weight loss. For investors it matters because IBD drives steady demand for medications, ongoing clinical trials, medical devices and diagnostics; think of it as a chronic maintenance market where successful treatments can create predictable, long‑term revenue streams and regulatory milestones can move stock prices.

biologic therapy medical

"Vedolizumab is a biologic therapy approved (under the trade name ENTYVIO) for in"

Biologic therapy are medicines made from living cells or their parts — such as proteins, antibodies or engineered cells — that treat disease by precisely targeting biological processes rather than using simple chemical compounds. They matter to investors because they often carry higher prices, require specialized manufacturing and strict regulatory approval, and can create large gains or losses depending on clinical results, patent protections and competition; think of them as custom-made repairs versus off-the-shelf parts.

subcutaneous (SC) medical

"approved (under the trade name ENTYVIO) for intravenous (IV) and subcutaneous (S"

Subcutaneous (sc) means given or located just under the skin, into the thin layer of fatty tissue that sits between the skin and muscle — think of putting medicine into a small pocket beneath a coat rather than into deeper layers. For investors, the route matters because it affects how easy a treatment is to take, how quickly and steadily it works, and what kind of devices or manufacturing processes are needed, all of which influence patient adoption, costs and market potential.

AI-generated analysis. Not financial advice.

Agreement provides Takeda with exclusive access to ENHANZE^® drug delivery technology for vedolizumab

SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive license agreement with Takeda in December 2025. The agreement provides Takeda with access to Halozyme's ENHANZE^® drug delivery technology, the leading proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), for use with vedolizumab. Vedolizumab is marketed globally as ENTYVIO. 

"Our collaboration with Takeda reflects our ongoing commitment to delivering innovative solutions that enhance the patient experience, with the goal of helping patients spend less time managing their therapy and more time living their lives," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "Our new collaboration reinforces the broad applicability and value of the ENHANZE technology across multiple therapeutic areas."

"People living with ulcerative colitis and Crohn's disease, as well as their health care providers, need flexible treatment options that match evolving needs and priorities in disease management," said Robert Hollowell, M.D., Head of Global Product and Launch Strategy, GI and Inflammation at Takeda. "Our collaboration is another example of our commitment to the IBD community and leadership in this therapeutic area. It is an exciting opportunity to potentially enable vedolizumab to benefit even more patients around the world, and integrate even more seamlessly into patients' lives."

Under the terms of the agreement, Takeda will make an upfront payment to Halozyme, and potential future development and commercial milestone payments. Halozyme will also be entitled to up to low-mid single digit royalties on sales of products containing vedolizumab in combination with ENHANZE^®.

Crohn's disease and ulcerative colitis are the two main forms of inflammatory bowel disease (IBD), characterized by chronic inflammation of the gastrointestinal tract. Both conditions can result in serious complications. It is estimated that more than 10 million people across the globe will be living with IBD within the next decade, reflecting a growing burden of IBD.

Vedolizumab is a biologic therapy approved (under the trade name ENTYVIO) for intravenous (IV) and subcutaneous (SC) administration (approvals vary by market). ENTYVIO is approved for use in adults with moderately to severely active Crohn's disease or ulcerative colitis. Please click for Entyvio Full U.S. Prescribing Information and for SmPC.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.

Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson, Eli Lilly, and argenx.

Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^® and XYOSTED^®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE^®, the possible method of action of ENHANZE^®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and statements concerning certain other potential benefits of ENHANZE^® including facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery and potentially lowering the treatment burden and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of Halozyme's ENHANZE^® partner (including the potential regulatory approval and launch of ENHANZE^® products as a result of such efforts and the potential future market opportunity for such products) and Halozyme's potential receipt of an upfront payment and payments associated with achievement of certain development and commercial milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue" and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether development and commercial milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Contacts

Tram Bui
Halozyme
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-announces-global-collaboration-and-license-agreement-with-takeda-to-develop-and-commercialize-vedolizumab-with-enhanze-302656038.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

What did Halozyme and Takeda announce about vedolizumab on January 8, 2026?

They announced a global collaboration and exclusive license (signed December 2025) for Halozyme's ENHANZE technology to be used with vedolizumab.

How will Halozyme be compensated under the Takeda agreement (HALO)?

Halozyme will receive an upfront payment, potential future development and commercial milestone payments, and up to low-mid single digit royalties on combined-product sales.

What is ENHANZE and how does it relate to ENTYVIO (vedolizumab)?

ENHANZE is Halozyme's rHuPH20 drug delivery technology; the agreement gives Takeda access to ENHANZE for vedolizumab (marketed as ENTYVIO).

Does the Takeda collaboration change vedolizumab approvals for subcutaneous use?

Vedolizumab is approved for IV and SC administration in some markets, but approvals vary by market; the collaboration targets use with ENHANZE.

When was the Halozyme–Takeda license agreement signed and which stock symbol is affected?

The agreement was signed in December 2025 and concerns Halozyme, ticker HALO.